| ISSN |
2222-0682 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Farah Alam, Huma Siddiqui, Arpna Nihal, Madiha Andleeb, Amna Qamar Uz Zaman, Mehwish Imam Khushk, Fatima Hussain, Rahul Rai, Fasiha Bakhtawar Fatima, Danaish Kumar, Syed Ali Farhan Abbas Rizvi, Shafaq Jabeen, Inshal Jawed, Umair Qadir and Mohammad Ali Zakeri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Inshal Jawed, Chief Physician, Senior Researcher, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com |
| Key Words |
Multiple myeloma; Corticosteroids; Monoclonal antibodies; Dexamethasone; Daratumumab; Elotuzumab; Isatuximab; Systematic review; Chemotherapy; Efficacy |
| Core Tip |
Corticosteroids and monoclonal antibodies (mAbs) deliver extensive therapeutic value to patients with multiple myeloma (MM) by providing survival improvements, particularly for people with relapsed or refractory disease. The essential medication dexamethasone, alongside other corticosteroids, has long proved beneficial in treatment regimens because it decreases tumor size and works better with other treatments. The development of daratumumab and other monoclonal antibodies introduced specific tumor cell antigen targeting, producing significant study results for high-risk patients. Modern advancements in cancer therapy have produced promising results, although ongoing research aims to address corticosteroid-related long-term effects, prevent infusion responses in mAbs, and decrease their costly nature. |
| Publish Date |
2026-02-10 10:35 |
| Citation |
Alam F, Siddiqui H, Nihal A, Andleeb M, Zaman AQU, Khushk MI, Hussain F, Rai R, Fatima FB, Kumar D, Rizvi SAFA, Jabeen S, Jawed I, Qadir U, Zakeri MA. Advancing multiple myeloma therapy: A systematic analysis of corticosteroids and monoclonal antibodies as dual therapeutic agents. World J Methodol 2026; 16(1): 107864 |
| URL |
https://www.wjgnet.com/2222-0682/full/v16/i1/107864.htm |
| DOI |
https://dx.doi.org/10.5662/wjm.v16.i1.107864 |
